Odonate Therapeutics, which is developing oral chemotherapy drugs, filed on Monday with the SEC to raise up to $173 million in an initial public offering.
The San Diego, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol ODT. Odonate Therapeutics filed confidentially on September 29, 2017. Goldman Sachs, Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
